High Serum Level of Plasminogen Activator Inhibitor-1 Predicts Histological Grade of Intracerebral Gliomas

• Published in: Anticancer research Vol. 28; no. 1B; pp. 415 - 418
• Main Authors: IWADATE, Yasuo, HAYAMA, Masayo, ADACHI, Akihiko, MATSUTANI, Tomoo, NAGAI, Yuichiro, HIWASA, Takaki, SAEKI, Naokatsu
• Format: Journal Article
• Language: English
• Published: Attiki International Institute of Anticancer Research 01.01.2008
• Subjects: Adolescent; Adult; Aged; Biological and medical sciences; Biomarkers, Tumor - biosynthesis; Biomarkers, Tumor - blood; Brain Neoplasms - blood; Brain Neoplasms - pathology; Female; Glioma - blood; Glioma - pathology; Humans; Immunohistochemistry; Male; Medical sciences; Middle Aged; Neurology; Plasminogen Activator Inhibitor 1 - biosynthesis; Plasminogen Activator Inhibitor 1 - blood; Tumors; Tumors of the nervous system. Phacomatoses; Nervous system diseases; Enzyme; Central nervous system; Biological marker; Histology; Intracerebral; Malignant tumor; Encephalon; protease; Plasminogen activator inhibitor 1; Peptidases; Cancerology; Glioma; serum marker; Central nervous system disease; Hydrolases; Serum; Predictive factor; plasminogen activator inhibitor-1 (PAI-1); Cancer
• ISSN: 0250-7005; 1791-7530

Background: No serum marker is currently available for the diagnosis and treatment of gliomas. Plasminogen activator inhibitor-1 (PAI-1) controls the proteolytic activity in cancer cells and cellular migration during angiogenesis. Patients and Methods: To verify the potential of PAI-1 as a serum marker for gliomas, the serum PAI-1 concentrations were measured by ELISA in 57 glioma patients and 34 healthy volunteers. Results: We found significantly higher serum levels in the patients with high-grade gliomas than in the healthy volunteers (p=0.0009, unpaired t-test) and those with low-grade tumors (p=0.0074). Furthermore, high-grade glioma patients with a low serum level of PAI-1 survived significantly longer than those with high levels (p=0.0082). Immunohistochemical analysis using anti-PAI-1 antibody revealed dense and spotty staining in the high-grade tumor tissues from the patients with high serum PAI-1 levels. Conclusion: These results suggest that the serum PAI-1 level can be a marker for the prediction of histological grade in intracerebral glioma.